Lung Cancer Clinical Trials

• Adult (≥ 18 years), all genders, capable of signing informed consent.

• Histologically- or cytologically- confirmed diagnosis of metastatic squamous NSCLC, metastasis can be regional lymph nodes or distant organs.

• Radiographic progression after treatment with the most recent line of treatment being either 3a or 3b:

‣ At least 12 weeks of PD-1/PD-L1 inhibitor in combination with platinum-based chemotherapy;

⁃ Prior treatment with at least 2 cycles of a platinum-based chemotherapy, followed by at least 12 weeks of standard doses of PD-1 or PD-L1 inhibitor-based immunotherapy.

• Antibodies against CTLA-4, LAG-3, TIGIT, VEGF or VEGFR in combination with PD-1/PD-L1 inhibitor are allowed.

• At least one measurable tumor lesion according to RECIST 1.1.

• ECOG score of 0 or 1.

• Adequate organ functions. Serum LDH level ≤ 2xULN.

• Life expectancy ≥ 3 months.